Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine

被引:94
|
作者
Kessler, Robert M.
Ansari, M. Sib
Riccardi, Patrizia
Li, Rui
Jayathilake, Karuna
Dawant, Benoit
Meltzer, Herbert Y.
机构
[1] Vanderbilt Univ, Sch Med, Dept Radiol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Elect Engn & Comp Sci, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37232 USA
关键词
PET; clozapine; quetiapine; antipsychotic drugs; dopamine D-2 receptor occupancy;
D O I
10.1038/sj.npp.1301108
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Clozapine and quetiapine have a low incidence of extrapyramidal side effects at clinically effective doses, which appears to be related to their significantly lower occupancy of striatal dopamine D-2 receptors (DA D(2)r) compared to typical antipsychotic drugs (APDs). Animal studies have indicated that clozapine and quetiapine produce selective effects on cortical and limbic regions of the brain and in particular on dopaminergic neurotransmission in these regions. Previous PET and SPECT studies have reported conflicting results regarding whether clozapine produces preferential occupancy of cortical DA D(2)r. To examine whether clozapine and/or quetiapine produce preferential occupancy of DA D(2)r in cortex and limbic regions, we studied the occupancy of putamenal, ventral striatal, thalamic, amygdala, substantia nigra, and temporal cortical DA D(2)r using PET with [F-18]fallypride in six schizophrenic subjects receiving clozapine monotherapy and in seven schizophrenic subjects receiving quetiapine monotherapy. Doses were chosen clinically to minimize psychopathology at tolerable levels of side effects such as drowsiness. All had minimal positive symptoms at the time of the study. Regional receptor occupancies were estimated using mean regional DA D(2)r levels calculated for 10 off-medication schizophrenic subjects. Both clozapine and quetiapine produced lower levels of putamenal DA D(2)r occupancy than those reported for typical APDs, 47.8 and 33.5%, respectively. Clozapine produced preferential occupancy of temporal cortical vs putamenal DA D(2)r, 59.8% (p = 0.05, corrected for multiple comparisons), and significantly lower levels of occupancy in the substantia nigra, 18.4% (p = 0.0015, corrected for multiple comparisons). Quetiapine also produced preferential occupancy of temporal cortical DA D(2)r, 46.9% (p = 0.03, corrected for multiple comparisons), but did not spare occupancy of substantia nigra DA D(2)r. The therapeutic effects of clozapine and quetiapine appear to be achieved at less than the 65% threshold for occupancy seen with typical APDs, consistent with the involvement of non-DA D(2)r mechanisms in at least partially mediating the therapeutic effects of these drugs. Preferential occupancy of cortical DA D(2)r, sparing occupancy of substantia nigra receptors, and non-DA D(2)r-mediated actions may contribute to the antipsychotic actions of these and other atypical APDs.
引用
收藏
页码:1991 / 2001
页数:11
相关论文
共 50 条
  • [1] Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine
    Robert M Kessler
    M Sib Ansari
    Patrizia Riccardi
    Rui Li
    Karuna Jayathilake
    Benoit Dawant
    Herbert Y Meltzer
    [J]. Neuropsychopharmacology, 2006, 31 : 1991 - 2001
  • [2] Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas
    Vernaleken, Ingo
    Janouschek, Hildegard
    Raptis, Mardjan
    Hellmann, Sandra
    Veselinovic, Tanja
    Broecheler, Anno
    Boy, Christian
    Cumming, Paul
    Hiemke, Christoph
    Roesch, Frank
    Schaefer, Wolfgang M.
    Gruender, Gerhard
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (07): : 951 - 960
  • [3] Occupancy of striatal and extrastriatal dopamine D2 receptors by antipsychotic drugs
    Kessler, RM
    Ansari, MS
    Lui, R
    Dawant, R
    Meltzer, HY
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S5 - S5
  • [4] Occupancy of striatal and extrastriatal dopamine D2 receptors by atypical antipsychotic drugs.
    Kessler, RM
    Ansari, SM
    Li, R
    Dawant, B
    Lee, M
    Meltzer, HY
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 15P - 15P
  • [5] Occupancy of Striatal and Extrastriatal Dopamine D2/D3 Receptors by Olanzapine and Haloperidol
    Robert M Kessler
    Mohammad Sib Ansari
    Patrizia Riccardi
    Rui Li
    Karuna Jayathilake
    Benoit Dawant
    Herbert Y Meltzer
    [J]. Neuropsychopharmacology, 2005, 30 : 2283 - 2289
  • [6] Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol
    Kessler, RM
    Ansari, MS
    Riccardi, P
    Li, R
    Jayathilake, K
    Dawant, B
    Meltzer, HY
    [J]. NEUROPSYCHOPHARMACOLOGY, 2005, 30 (12) : 2283 - 2289
  • [7] Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride
    Lawrence S Kegeles
    Mark Slifstein
    W Gordon Frankle
    Xiaoyan Xu
    Elizabeth Hackett
    Sung-A Bae
    Robyn Gonzales
    Jong-Hoon Kim
    Beatriz Alvarez
    Roberto Gil
    Marc Laruelle
    Anissa Abi-Dargham
    [J]. Neuropsychopharmacology, 2008, 33 : 3111 - 3125
  • [8] The role of extrastriatal dopamine D2 receptors in schizophrenia
    Takahashi, Hidehiko
    Higuchi, Makoto
    Suhara, Tetsuya
    [J]. BIOLOGICAL PSYCHIATRY, 2006, 59 (10) : 919 - 928
  • [9] Dose-Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F] Fallypride
    Kegeles, Lawrence S.
    Slifstein, Mark
    Frankle, W. Gordon
    Xu, Xiaoyan
    Hackett, Elizabeth
    Bae, Sung-A
    Gonzales, Robyn
    Kim, Jong-Hoon
    Alvarez, Beatriz
    Gil, Roberto
    Laruelle, Marc
    Abi-Dargham, Anissa
    [J]. NEUROPSYCHOPHARMACOLOGY, 2008, 33 (13) : 3111 - 3125
  • [10] Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans
    Fujita, M
    Verhoeff, NPLG
    Varrone, A
    Zoghbi, SS
    Baldwin, RM
    Jatlow, PA
    Anderson, GM
    Seibyl, JP
    Innis, RB
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 387 (02) : 179 - 188